Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
- Author:
Jisun PARK
1
;
Yunseon CHOI
;
Ki Jung AHN
;
Sung Kwang PARK
;
Heunglae CHO
;
Ji Young LEE
Author Information
- Publication Type:Original Article
- Keywords: Lung neoplasms; Positron-emission tomography; Standardized uptake value; Stereotactic body radiotherapy; Progression-free survival
- MeSH: Disease-Free Survival; Electrons; Follow-Up Studies; Humans; Lung Neoplasms; Lung; Neoplasm, Residual; Positron-Emission Tomography; Positron-Emission Tomography and Computed Tomography; Prognosis; Radiosurgery; Recurrence; Retrospective Studies; ROC Curve
- From:Radiation Oncology Journal 2019;37(1):30-36
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study aimed to identify the feasibility of the maximum standardized uptake value (SUVmax) on baseline 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) as a predictive factor for prognosis in early stage primary lung cancer treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: Twenty-seven T1-3N0M0 primary lung cancer patients treated with curative SBRT between 2010 and 2018 were retrospectively evaluated. Four patients (14.8%) treated with SBRT to address residual tumor after wedge resection and one patient (3.7%) with local recurrence after resection were included. The SUVmax at baseline PET/CT was assessed to determine its relationship with prognosis after SBRT. Patients were divided into two groups based on maximum SUVmax on pre-treatment FDG PET/CT, estimated by receiver operating characteristic curve. RESULTS: The median follow-up period was 17.7 months (range, 2.3 to 60.0 months). The actuarial 2-year local control, progressionfree survival (PFS), and overall survival were 80.4%, 66.0%, and 78.2%, respectively. With regard to failure patterns, 5 patients exhibited local failure (in-field failure, 18.5%), 1 (3.7%) experienced regional nodal relapse, and other 2 (7.4%) developed distant failure. SUVmax was significantly correlated with progression (p = 0.08, optimal cut-off point SUVmax > 5.1). PFS was significantly influenced by pretreatment SUVmax (SUVmax > 5.1 vs. SUVmax ≤ 5.1; p = 0.012) and T stage (T1 vs. T2-3; p = 0.012). CONCLUSION: SUVmax at pre-treatment FDG PET/CT demonstrated a predictive value for PFS after SBRT for lung cancer.
